Behavior Activation for Grief

Phase-Based Progress Estimates
Texas Tech University, Lubbock, TX
Grief+3 More
Mindfulness Based Cognitive Therapy - Behavioral
All Sexes
What conditions do you have?

Study Summary

The overarching goal of this project is to evaluate if evidence-based interventions can reduce PDG, burden, and stress in informal caregivers of individuals with dementia

Eligible Conditions

  • Grief
  • Burden, Caregiver
  • Mental Health Issue

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: through study completion, an average of 6 months

Month 6
Perceived Stress Scale
Prolonged Grief Scale-12 (measuring pre-death grief)
Zarit Burden Inventory (ZBI)

Trial Safety

Trial Design

2 Treatment Groups

Behavior Activation
1 of 2
Mindfulness Based Cognitive Therapy
1 of 2
Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Behavior Activation · No Placebo Group · N/A

Behavior Activation
Experimental Group · 1 Intervention: Behavior Activation · Intervention Types: Behavioral
Mindfulness Based Cognitive Therapy
Experimental Group · 1 Intervention: Mindfulness Based Cognitive Therapy · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Mindfulness Based Cognitive Therapy
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 6 months
Closest Location: Texas Tech University · Lubbock, TX
2014First Recorded Clinical Trial
1 TrialsResearching Grief
12 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are an informal caregiver of an individual with dementia.
You have a caregiver who is a family member or close friend.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.